DDMAC grows DTC group

Share this article:
The Division of Drug Marketing, Advertising & Communication (DDMAC) has added a second DTC review group to meet soaring demand for advertising approvals, said DTC group leader Melissa Moncavage.

DDMAC fielded 9,285 consumer promotions in 2005—up from 8,417 in 2004 and 6,099 in 2003. The number of DTC ads submitted is expected to climb again for 2006.

The second group, consisting of three reviewers and acting leader Christine Smith, will handle ads for neurology, psychiatry, cardiovascular, renal, reproductive , urology, anti-infective and anti-viral products. Moncavage's five-person team, including two reviewers and two social scientists, will cover those for oncology, medical imaging, hematology, dermatology, gastroenterology, pulmonary, rheumatology, analgesic, metabolism and endocrine products. 

The addition of the second DTC review team, first reported in The Pink Sheet, has fueled discussion between the agency and industry of a possible increase in PDUFA user fees. DDMAC also maintains four review groups dedicated to professional advertising. The agency received 39,153 pieces of professional promotion for review in 2005.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...